A Response to: Letter to the Editor Regarding "Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx)".
作者信息
Attal Sepideh
机构信息
Pfizer PIO, 23-25 Avenue du Dr Lannelongue, 75668, Paris Cedex 14, France.
出版信息
Cardiol Ther. 2024 Dec;13(4):815-817. doi: 10.1007/s40119-024-00383-4. Epub 2024 Oct 23.
Abstract
摘要
相似文献
1
A Response to: Letter to the Editor Regarding "Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx)".对《致编辑的信：关于“61毫克氯苯唑酸的患者特征与持续性？对德国法定医疗保险数据（IQVIA™ LRx）的回顾性分析”》的回应
Cardiol Ther. 2024 Dec;13(4):815-817. doi: 10.1007/s40119-024-00383-4. Epub 2024 Oct 23.
2
Letter to the Editor Regarding 'Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx)'.致编辑的信：关于“61毫克氯苯唑酸的患者特征与持续性？对德国法定医疗保险数据（IQVIA™ LRx）的回顾性分析”
Cardiol Ther. 2024 Dec;13(4):811-814. doi: 10.1007/s40119-024-00382-5. Epub 2024 Oct 23.
3
Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx).61毫克氯苯唑酸的患者特征与用药依从性？对德国法定医疗保险数据（IQVIA™ LRx）的回顾性分析
Cardiol Ther. 2024 Jun;13(2):369-378. doi: 10.1007/s40119-024-00365-6. Epub 2024 Apr 13.
4
German longitudinal prescription database (LRx): Description of characteristics, use in pharmacoepidemiological research, and limitations
.德国纵向处方数据库（LRx）：特征描述、在药物流行病学研究中的应用及局限性
Int J Clin Pharmacol Ther. 2024 Jan;62(1):20-28. doi: 10.5414/CP204485.
5
Influenza vaccination coverage in the 2004/05, 2005/06, and 2006/07 seasons: a secondary data analysis based on billing data of the German associations of statutory health insurance physicians.2004/05、2005/06 和 2006/07 流感季节的疫苗接种覆盖率：基于德国法定医疗保险医师协会计费数据的二次数据分析。
Dtsch Arztebl Int. 2010 Dec;107(48):845-50. doi: 10.3238/arztebl.2010.0845. Epub 2010 Dec 3.
6
Baseline characteristics and secondary medication adherence among Medicare patients diagnosed with transthyretin amyloid cardiomyopathy and/or receiving tafamidis prescriptions: A retrospective analysis of a Medicare cohort.经转甲状腺素蛋白淀粉样变心肌病诊断和/或接受他司美坦治疗的医疗保险患者的基线特征和二级药物依从性：医疗保险队列的回顾性分析。
J Manag Care Spec Pharm. 2022 Jul;28(7):766-777. doi: 10.18553/jmcp.2022.28.7.766.
7
[Compilation of Second Opinion Programs in the German Statutory Health Insurance].[德国法定医疗保险中第二诊疗意见项目汇编]
Gesundheitswesen. 2018 Oct;80(10):859-863. doi: 10.1055/s-0043-105576. Epub 2017 May 15.
8
[The German Statutory Accident Insurance: A successful example of a value-based healthcare structure].[德国法定事故保险：基于价值的医疗保健结构的成功范例]
Z Evid Fortbild Qual Gesundhwes. 2018 Feb;130:13-20. doi: 10.1016/j.zefq.2017.07.009. Epub 2017 Sep 1.
9
Analysis of second opinion programs provided by German statutory and private health insurance - a survey of statutory and private health insurers.德国法定和私人健康保险提供的第二诊疗意见计划分析——对法定和私人健康保险公司的调查。
BMC Health Serv Res. 2021 Mar 9;21(1):209. doi: 10.1186/s12913-021-06207-8.
10
Real-world characteristics and use patterns of patients treated with vericiguat: A nationwide longitudinal cohort study in Germany.在德国开展的一项全国性纵向队列研究：维立西呱治疗患者的真实世界特征和使用模式。
Eur J Clin Pharmacol. 2024 Jun;80(6):931-940. doi: 10.1007/s00228-024-03654-0. Epub 2024 Mar 12.
本文引用的文献
1
Letter to the Editor Regarding 'Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx)'.致编辑的信：关于“61毫克氯苯唑酸的患者特征与持续性？对德国法定医疗保险数据（IQVIA™ LRx）的回顾性分析”
Cardiol Ther. 2024 Dec;13(4):811-814. doi: 10.1007/s40119-024-00382-5. Epub 2024 Oct 23.
2
Anticoagulation in Atrial Fibrillation Associated With Cardiac Amyloidosis: A Narrative Review.心脏淀粉样变性伴发心房颤动的抗凝治疗：一篇叙述性综述
Cureus. 2024 Jun 3;16(6):e61557. doi: 10.7759/cureus.61557. eCollection 2024 Jun.
3
Prognostic Value of Standard Heart Failure Medication in Patients with Cardiac Transthyretin Amyloidosis.标准心力衰竭药物治疗对心脏转甲状腺素蛋白淀粉样变患者的预后价值
J Clin Med. 2024 Apr 12;13(8):2257. doi: 10.3390/jcm13082257.
4
Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx).61毫克氯苯唑酸的患者特征与用药依从性？对德国法定医疗保险数据（IQVIA™ LRx）的回顾性分析
Cardiol Ther. 2024 Jun;13(2):369-378. doi: 10.1007/s40119-024-00365-6. Epub 2024 Apr 13.
5
Tolerability and effectiveness of beta-blockers in patients with cardiac amyloidosis: A systematic review and meta-analysis.β受体阻滞剂在心肌淀粉样变患者中的耐受性和有效性：系统评价和荟萃分析。
Int J Cardiol. 2024 May 1;402:131813. doi: 10.1016/j.ijcard.2024.131813. Epub 2024 Jan 24.
6
Conventional heart failure therapy in cardiac ATTR amyloidosis.心脏肌球蛋白重链ATTR 淀粉样变的常规心力衰竭治疗。
Eur Heart J. 2023 Aug 14;44(31):2893-2907. doi: 10.1093/eurheartj/ehad347.
7
Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years.心脏ATTR 淀粉样变 20 年的早期诊断影响。
Circulation. 2022 Nov 29;146(22):1657-1670. doi: 10.1161/CIRCULATIONAHA.122.060852. Epub 2022 Nov 3.
8
Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, the Future, and the Challenges.转甲状腺素蛋白淀粉样心肌病的治疗：当前选择、未来展望与挑战
J Clin Med. 2022 Apr 12;11(8):2148. doi: 10.3390/jcm11082148.
9
Beta-Blocker Exposure and Survival in Patients With Transthyretin Amyloid Cardiomyopathy.β受体阻滞剂暴露与转甲状腺素蛋白淀粉样变心肌病患者的生存。
Mayo Clin Proc. 2022 Feb;97(2):261-273. doi: 10.1016/j.mayocp.2021.08.006. Epub 2021 Nov 19.
10
Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.心脏淀粉样变性的诊断与治疗。欧洲心脏病学会心肌和心包疾病工作组立场声明。
Eur J Heart Fail. 2021 Apr;23(4):512-526. doi: 10.1002/ejhf.2140. Epub 2021 Apr 7.
Zotero 插件